2011 Breast Cancer Symposium
SAN FRANCISCO - Locoregional failures in patients who underwent
breast-conservation therapy were not driven by the timing of chemotherapy,
according to research presented here.
Elizabeth Mittendorf, MD, assistant professor in the department
of surgical oncology at The University of Texas MD Anderson Cancer Center, and
colleagues evaluated whether women undergoing breast-conservation surgery first
or neoadjuvant chemotherapy first had better local control rates in the long
Elizabeth Mittendorf, MD
The study included 2,984 patients who underwent
breast-conservation therapy and whole-breast irradiation from
1987 to 2005. They compared the outcomes of patients who underwent surgery
first with the outcomes of patients who underwent neoadjuvant chemotherapy
first. Most patients (78%) underwent surgery first.
The 5-year locoregional recurrence rate was 97% for women who underwent
surgery first, and the 10-year rate was 94%. Among women who underwent
chemotherapy first, the 5-year locoregional recurrence rate was 93%, and the
10-year rate was 90%. After adjusting for clinical stage at presentation, there
were no differences in
control between either group of women. Neoadjuvant chemotherapy lowered the
cancer stage in nearly half of patients with stage II or III disease before
chemotherapy, allowing breast-conservation therapy.
"Appropriately selected patients achieve high rates of local-regional
control with breast-conservation therapy," Mittendorf said. "Local-regional
recurrence after breast-conservation therapy is driven by biologic factors, not
timing of chemotherapy."
For more information:
Disclosure: Dr. Mittendorf reports no relevant financial
Earn CME this spring at the HemOnc Today Breast Cancer Review & Perspective meeting to be held March 23-24, 2012 at the Hilton San Diego Bayfront. See details at HemOncTodayBreastCancer.com.